Closing the data loop in AI-driven drug discovery
MIT Tech Review reports on how artificial intelligence aims to address drug discovery challenges such as rising development costs and tight market pressures. Pharmaceutical creation faces significant obstacles due to Eroom's Law, which reflects how the cost of developing new drugs has roughly doubled every nine years since the 1950s. As a result, launching a new drug to market currently takes an average of 10-15 years.
Key Takeaways
- Drug discovery is a high-cost and high-risk undertaking that operates under increasing pressure from a marketplace defined by first-mover advantage.
Historical trends since the 1950s demonstrate that the expense of developing novel pharmaceuticals has roughly doubled every nine years, a pattern identified as Eroom's Law.
- Furthermore, successfully bringing a modern drug to market requires an average timeframe of 10-15 years.
These severe operational obstacles highlight why closing the data loop using artificial intelligence has become a focus for drug discovery.
- High financial barriers and extended multi-year timelines underscore the necessity for data-driven methods that accelerate candidate selection and reduce failure rates.
Overcoming the structural slowdown described by Eroom's Law serves as a major test case for evaluating machine learning applications in complex biomedical domains.
- Pharmaceutical development costs have roughly doubled every nine years since the 1950s.
The continuous rise in drug creation expenses over recent decades is called Eroom's Law.
- Bringing a new pharmaceutical product to market currently requires an average of 10-15 years.
Drug discovery is a high-cost and high-risk undertaking that operates under increasing pressure from a marketplace defined by first-mover advantage. Historical trends since the 1950s demonstrate that the expense of developing novel pharmaceuticals has roughly doubled every nine years, a pattern identified as Eroom's Law. Furthermore, successfully bringing a modern drug to market requires an average timeframe of 10-15 years.
These severe operational obstacles highlight why closing the data loop using artificial intelligence has become a focus for drug discovery. High financial barriers and extended multi-year timelines underscore the necessity for data-driven methods that accelerate candidate selection and reduce failure rates. Overcoming the structural slowdown described by Eroom's Law serves as a major test case for evaluating machine learning applications in complex biomedical domains.
Pharmaceutical development costs have roughly doubled every nine years since the 1950s. The continuous rise in drug creation expenses over recent decades is called Eroom's Law. Bringing a new pharmaceutical product to market currently requires an average of 10-15 years.
For more details please read the original article at MIT Tech Review.
Continue Learning
Comments
Comments appear only after moderation. Your email identifies your submission to the moderator and is never displayed here.
No approved comments yet.